INS365 Ophthalmic Solution
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis Sicca
Conditions
Keratoconjunctivitis Sicca
Trial Timeline
Apr 1, 2002 → Mar 1, 2003
NCT ID
NCT00037661About INS365 Ophthalmic Solution
INS365 Ophthalmic Solution is a phase 3 stage product being developed by Merck for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT00037661. Target conditions include Keratoconjunctivitis Sicca.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00037661 | Phase 3 | Completed |
Competing Products
15 competing products in Keratoconjunctivitis Sicca
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 77 |
| FK506 + placebo | Astellas Pharma | Phase 3 | 77 |
| OTX-101 0.09% | Sun Pharmaceutical | Phase 3 | 77 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 65 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 77 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 52 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 85 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Tasocitinib + Tasocitinib + vehicle for Tasocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo | Rigel Pharmaceuticals | Phase 1 | 25 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |
| CF101 | Can Fite Biopharma | Phase 3 | 69 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 44 |